[HTML][HTML] Mammalian nicotinic acetylcholine receptors: from structure to function
EX Albuquerque, EFR Pereira… - Physiological …, 2009 - journals.physiology.org
… (148) to study chromaffin cells, and was adapted by Albuquerque to study the α7 nAChR
function (11–13, 320) with the inclusion of special ejection and uptake valves. The U-tube …
function (11–13, 320) with the inclusion of special ejection and uptake valves. The U-tube …
Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms
…, P Georgiou, EFR Pereira, EX Albuquerque… - Pharmacological …, 2018 - ASPET
Ketamine, a racemic mixture consisting of (S)- and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …
International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits
…, JP Changeux, N le Novère, EX Albuquerque… - Pharmacological …, 1999 - ASPET
Nicotinic acetylcholine receptors (nACh receptors2) in jawed vertebrates are prototypical
members of the multisubunit, neurotransmitter-gated superfamily of ion channels (ionotropic …
members of the multisubunit, neurotransmitter-gated superfamily of ion channels (ionotropic …
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
…, XP Huang, CL Mayo, IW Wainer, EX Albuquerque… - Nature, 2016 - nature.com
… A specially adapted U-tube developed in the Albuquerque laboratory was used to apply
NMDA (50 μM) to the neurons for the NMDA-evoked current experiments. NMDA-evoked …
NMDA (50 μM) to the neurons for the NMDA-evoked current experiments. NMDA-evoked …
The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications
…, R Schwarcz, EX Albuquerque - Journal of …, 2001 - Soc Neuroscience
The tryptophan metabolite kynurenic acid (KYNA) has long been recognized as an NMDA
receptor antagonist. Here, interactions between KYNA and the nicotinic system in the brain …
receptor antagonist. Here, interactions between KYNA and the nicotinic system in the brain …
Choline is a selective agonist of α7 nicotinic acetylcholine receptors in the rat brain neurons
…, A Maelicke, EX Albuquerque - European Journal of …, 1997 - Wiley Online Library
In the present study, we demonstrate that choline, a precursor of acetylcholine (ACh) and a
product of acetylcholine hydrolysis by acetylcholinesterase (AChE), acts as an efficient and …
product of acetylcholine hydrolysis by acetylcholinesterase (AChE), acts as an efficient and …
Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes.
M Alkondon, EX Albuquerque - Journal of pharmacology and experimental …, 1993 - ASPET
Nicotinic acetylcholine receptors present on cultured hippocampal neurons from fetal rats
were characterized by means of whole-cell patch-clamp technique, using a number of …
were characterized by means of whole-cell patch-clamp technique, using a number of …
Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function
EX Albuquerque, M Alkondon, EFR Pereira… - … of Pharmacology and …, 1997 - ASPET
Mr. Chairman, ladies and gentlemen, it is an honor to receive from the American Society of
Pharmacology and Experimental Therapeutics the 1996 Otto Krayer Award sponsored by …
Pharmacology and Experimental Therapeutics the 1996 Otto Krayer Award sponsored by …
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors
…, EFR Pereira, H Lübbert, EX Albuquerque… - … of Pharmacology and …, 2003 - ASPET
… From an ex vivo study using human brain postmortem and fresh cortical biopsy samples,
IC 50 values in the range of 2.8 to 3.2 μM for the frontal cortex and the hippocampus were …
IC 50 values in the range of 2.8 to 3.2 μM for the frontal cortex and the hippocampus were …
Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease
…, A Fehrenbacher, J Ludwig, EX Albuquerque… - Biological …, 2001 - Elsevier
Cholinesterase inhibitors are the only approved drug treatment for patients with mild to
moderately severe Alzheimer’s disease. Interestingly, the clinical potency of these drugs does not …
moderately severe Alzheimer’s disease. Interestingly, the clinical potency of these drugs does not …